Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells

M. T. Petrucci, M. R. Ricciardi, C. Gregorj, C. Ariola, F. Mazzola, M. Fogli, R. M. Lemoli, A. Tafuri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this study we report our data on effects of early-acting megakaryocyte growth factors, particularly the c-mpl ligand also known as thrombopoietin (TPO) and interleukin-11 (IL-11), on cell proliferation and apoptosis (Apo) of primary acute myeloid leukemia (AML) cells. A proliferative response to TPO was noticed in the majority of AML samples (17/19) with an average increase of S-phase cells from 7.8% ± 1.5 to 14.5% ± 2.1 (p=0.0006). Resulting cell cycle activation did not always correlate with expression of the c-mpl receptor, although it was coupled, in the majority of samples, by an average decrease of apoptotic cells from 13% ±0.7 to 8.8% ±1.8 (p=0.05). Clonogenic cell growth (CFU-L) was confirmed in 5/17 of the samples with a mean colony number of 21.4 ±9.6 × 105 cells plated. Conversely, effects of IL-11 on AML cells demonstrated that cell cycle changes (recruitment from G0 to S phase) were promoted only in a minority of samples (2/14) and there was little, if any, effect on CFU-L growth (mean colony number=17.5±9.5) or Apo (from 13% ±0.7 to 13.3±1.9). Combination of TPO with IL-11 induced a slight increase of clonogenic cell growth, while the addition of IL-3 or SCF to the c-mpl ligand significantly raised the mean colony numbers up to 119.2±68.3 and 52.9±22.1 × 105 cells plated, respectively. In summary, TPO shows activity on AML cells by stimulating their proliferation in a significant proportion of cases and generally protecting the majority of AML blast cells from induction of Apo. Conversely, IL-11 exerts little effect on the cell cycle activation and Apo. These data help to understand regulation of myeloid leukemia cell growth and should be considered in the clinical use of early-acting megakaryocyte growth factors in acute leukemia.

Original languageEnglish
Pages (from-to)179-190
Number of pages12
JournalLeukemia and Lymphoma
Volume40
Issue number1-2
Publication statusPublished - 2001

Fingerprint

Interleukin-11
Thrombopoietin
Megakaryocytes
Intercellular Signaling Peptides and Proteins
Leukemia
Acute Myeloid Leukemia
Myeloid Cells
Apoptosis
Cell Cycle
Growth
S Phase
Myeloid Leukemia
Interleukin-3
Cell Proliferation

Keywords

  • Apoptosis
  • Cell cycle
  • Early-acting megakaryocyte growth factors
  • Interleukin-11
  • Thrombopoietin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Petrucci, M. T., Ricciardi, M. R., Gregorj, C., Ariola, C., Mazzola, F., Fogli, M., ... Tafuri, A. (2001). Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells. Leukemia and Lymphoma, 40(1-2), 179-190.

Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells. / Petrucci, M. T.; Ricciardi, M. R.; Gregorj, C.; Ariola, C.; Mazzola, F.; Fogli, M.; Lemoli, R. M.; Tafuri, A.

In: Leukemia and Lymphoma, Vol. 40, No. 1-2, 2001, p. 179-190.

Research output: Contribution to journalArticle

Petrucci, MT, Ricciardi, MR, Gregorj, C, Ariola, C, Mazzola, F, Fogli, M, Lemoli, RM & Tafuri, A 2001, 'Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells', Leukemia and Lymphoma, vol. 40, no. 1-2, pp. 179-190.
Petrucci MT, Ricciardi MR, Gregorj C, Ariola C, Mazzola F, Fogli M et al. Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells. Leukemia and Lymphoma. 2001;40(1-2):179-190.
Petrucci, M. T. ; Ricciardi, M. R. ; Gregorj, C. ; Ariola, C. ; Mazzola, F. ; Fogli, M. ; Lemoli, R. M. ; Tafuri, A. / Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells. In: Leukemia and Lymphoma. 2001 ; Vol. 40, No. 1-2. pp. 179-190.
@article{93c9da416b724edcb0725eb9fe2b7e81,
title = "Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells",
abstract = "In this study we report our data on effects of early-acting megakaryocyte growth factors, particularly the c-mpl ligand also known as thrombopoietin (TPO) and interleukin-11 (IL-11), on cell proliferation and apoptosis (Apo) of primary acute myeloid leukemia (AML) cells. A proliferative response to TPO was noticed in the majority of AML samples (17/19) with an average increase of S-phase cells from 7.8{\%} ± 1.5 to 14.5{\%} ± 2.1 (p=0.0006). Resulting cell cycle activation did not always correlate with expression of the c-mpl receptor, although it was coupled, in the majority of samples, by an average decrease of apoptotic cells from 13{\%} ±0.7 to 8.8{\%} ±1.8 (p=0.05). Clonogenic cell growth (CFU-L) was confirmed in 5/17 of the samples with a mean colony number of 21.4 ±9.6 × 105 cells plated. Conversely, effects of IL-11 on AML cells demonstrated that cell cycle changes (recruitment from G0 to S phase) were promoted only in a minority of samples (2/14) and there was little, if any, effect on CFU-L growth (mean colony number=17.5±9.5) or Apo (from 13{\%} ±0.7 to 13.3±1.9). Combination of TPO with IL-11 induced a slight increase of clonogenic cell growth, while the addition of IL-3 or SCF to the c-mpl ligand significantly raised the mean colony numbers up to 119.2±68.3 and 52.9±22.1 × 105 cells plated, respectively. In summary, TPO shows activity on AML cells by stimulating their proliferation in a significant proportion of cases and generally protecting the majority of AML blast cells from induction of Apo. Conversely, IL-11 exerts little effect on the cell cycle activation and Apo. These data help to understand regulation of myeloid leukemia cell growth and should be considered in the clinical use of early-acting megakaryocyte growth factors in acute leukemia.",
keywords = "Apoptosis, Cell cycle, Early-acting megakaryocyte growth factors, Interleukin-11, Thrombopoietin",
author = "Petrucci, {M. T.} and Ricciardi, {M. R.} and C. Gregorj and C. Ariola and F. Mazzola and M. Fogli and Lemoli, {R. M.} and A. Tafuri",
year = "2001",
language = "English",
volume = "40",
pages = "179--190",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1-2",

}

TY - JOUR

T1 - Thrombopoietin, interleukin -11, and early-acting megakaryocyte growth factors in human myeoloid leukemia cells

AU - Petrucci, M. T.

AU - Ricciardi, M. R.

AU - Gregorj, C.

AU - Ariola, C.

AU - Mazzola, F.

AU - Fogli, M.

AU - Lemoli, R. M.

AU - Tafuri, A.

PY - 2001

Y1 - 2001

N2 - In this study we report our data on effects of early-acting megakaryocyte growth factors, particularly the c-mpl ligand also known as thrombopoietin (TPO) and interleukin-11 (IL-11), on cell proliferation and apoptosis (Apo) of primary acute myeloid leukemia (AML) cells. A proliferative response to TPO was noticed in the majority of AML samples (17/19) with an average increase of S-phase cells from 7.8% ± 1.5 to 14.5% ± 2.1 (p=0.0006). Resulting cell cycle activation did not always correlate with expression of the c-mpl receptor, although it was coupled, in the majority of samples, by an average decrease of apoptotic cells from 13% ±0.7 to 8.8% ±1.8 (p=0.05). Clonogenic cell growth (CFU-L) was confirmed in 5/17 of the samples with a mean colony number of 21.4 ±9.6 × 105 cells plated. Conversely, effects of IL-11 on AML cells demonstrated that cell cycle changes (recruitment from G0 to S phase) were promoted only in a minority of samples (2/14) and there was little, if any, effect on CFU-L growth (mean colony number=17.5±9.5) or Apo (from 13% ±0.7 to 13.3±1.9). Combination of TPO with IL-11 induced a slight increase of clonogenic cell growth, while the addition of IL-3 or SCF to the c-mpl ligand significantly raised the mean colony numbers up to 119.2±68.3 and 52.9±22.1 × 105 cells plated, respectively. In summary, TPO shows activity on AML cells by stimulating their proliferation in a significant proportion of cases and generally protecting the majority of AML blast cells from induction of Apo. Conversely, IL-11 exerts little effect on the cell cycle activation and Apo. These data help to understand regulation of myeloid leukemia cell growth and should be considered in the clinical use of early-acting megakaryocyte growth factors in acute leukemia.

AB - In this study we report our data on effects of early-acting megakaryocyte growth factors, particularly the c-mpl ligand also known as thrombopoietin (TPO) and interleukin-11 (IL-11), on cell proliferation and apoptosis (Apo) of primary acute myeloid leukemia (AML) cells. A proliferative response to TPO was noticed in the majority of AML samples (17/19) with an average increase of S-phase cells from 7.8% ± 1.5 to 14.5% ± 2.1 (p=0.0006). Resulting cell cycle activation did not always correlate with expression of the c-mpl receptor, although it was coupled, in the majority of samples, by an average decrease of apoptotic cells from 13% ±0.7 to 8.8% ±1.8 (p=0.05). Clonogenic cell growth (CFU-L) was confirmed in 5/17 of the samples with a mean colony number of 21.4 ±9.6 × 105 cells plated. Conversely, effects of IL-11 on AML cells demonstrated that cell cycle changes (recruitment from G0 to S phase) were promoted only in a minority of samples (2/14) and there was little, if any, effect on CFU-L growth (mean colony number=17.5±9.5) or Apo (from 13% ±0.7 to 13.3±1.9). Combination of TPO with IL-11 induced a slight increase of clonogenic cell growth, while the addition of IL-3 or SCF to the c-mpl ligand significantly raised the mean colony numbers up to 119.2±68.3 and 52.9±22.1 × 105 cells plated, respectively. In summary, TPO shows activity on AML cells by stimulating their proliferation in a significant proportion of cases and generally protecting the majority of AML blast cells from induction of Apo. Conversely, IL-11 exerts little effect on the cell cycle activation and Apo. These data help to understand regulation of myeloid leukemia cell growth and should be considered in the clinical use of early-acting megakaryocyte growth factors in acute leukemia.

KW - Apoptosis

KW - Cell cycle

KW - Early-acting megakaryocyte growth factors

KW - Interleukin-11

KW - Thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=0035145597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035145597&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 179

EP - 190

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -